share_log

Returns At Yifeng Pharmacy Chain (SHSE:603939) Appear To Be Weighed Down

Returns At Yifeng Pharmacy Chain (SHSE:603939) Appear To Be Weighed Down

益豐藥房(SHSE:603939)的股價似乎受到拖累。
Simply Wall St ·  07/16 20:01

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to notice a trend of growing return on capital employed (ROCE) and alongside that, an expanding base of capital employed. Basically this means that a company has profitable initiatives that it can continue to reinvest in, which is a trait of a compounding machine. So, when we ran our eye over Yifeng Pharmacy Chain's (SHSE:603939) trend of ROCE, we liked what we saw.

要找到一支多倍股票,我們應該在業務中尋找哪些基礎趨勢?通常,我們會注意到ROCE(資本僱用回報率)增長的趨勢,以及相應的資本僱用基數擴大。這基本上意味着公司有盈利的計劃,可以持續投資,這是複合機器的特點。因此,在審視益豐藥房(SHSE:603939)的ROCE趨勢時,我們很喜歡我們所看到的東西。

What Is Return On Capital Employed (ROCE)?

我們對 Enphase Energy 的資本僱用回報率的看法:正如我們上面看到的,Enphase Energy 的資本回報率沒有提高,但它正在重新投資於業務。投資者必須認爲未來會有更好的前景,因爲股票表現良好,使持股五年以上的股東獲得了 690% 的收益。最終,如果基本趨勢持續存在,我們不會對它成爲一隻多頭股持有期很久很有信心。

If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a company generates from capital employed in its business. The formula for this calculation on Yifeng Pharmacy Chain is:

如果您以前沒有使用過ROCE,那麼它就是衡量公司從投資於業務中的資本中產生的「回報」(稅前利潤)的指標。在這個計算公式中,我們使用的是益豐藥房的指標:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

資產僱用回報率(ROCE)是指企業利潤,即企業稅前利潤除以企業投入的總資本(負債加股權)。如果ROCE高於企業財務成本的承受能力,那麼企業就會創造出更多的價值。

0.14 = CN¥2.1b ÷ (CN¥26b - CN¥11b) (Based on the trailing twelve months to March 2024).

0.14 = CN¥21億 ÷ (CN¥260億 - CN¥11b) (截至2024年3月的過去十二個月)。

Therefore, Yifeng Pharmacy Chain has an ROCE of 14%. In absolute terms, that's a satisfactory return, but compared to the Consumer Retailing industry average of 6.4% it's much better.

因此,益豐藥房的ROCE爲14%。就絕對值而言,這是一個令人滿意的回報,但與6.4%的消費零售行業平均水平相比要好得多。

big
SHSE:603939 Return on Capital Employed July 17th 2024
SHSE:603939 Return on Capital Employed July 17th 2024

In the above chart we have measured Yifeng Pharmacy Chain's prior ROCE against its prior performance, but the future is arguably more important. If you'd like, you can check out the forecasts from the analysts covering Yifeng Pharmacy Chain for free.

在上面的圖表中,我們已經測量了益豐藥房的先前ROCE與其先前表現,但未來可能更重要。如果您願意,可以免費檢查分析師對益豐藥房的預測。

What The Trend Of ROCE Can Tell Us

儘管如此,當我們看 enphase energy (納斯達克股票代碼:ENPH) 的時候,它似乎並沒有完全符合這些要求。

While the current returns on capital are decent, they haven't changed much. The company has employed 193% more capital in the last five years, and the returns on that capital have remained stable at 14%. 14% is a pretty standard return, and it provides some comfort knowing that Yifeng Pharmacy Chain has consistently earned this amount. Stable returns in this ballpark can be unexciting, but if they can be maintained over the long run, they often provide nice rewards to shareholders.

儘管當前資本回報率還不錯,但並沒有發生太大變化。公司在過去五年裏投入了193%的資本,而該資本的回報率保持在14%左右。14%是相當標準的回報率,知道益豐藥房一直能穩定地獲得這個數額還是令人感到安慰的。這個回報率穩定在這個範圍內可能會讓人覺得不夠刺激,但如果能在長期內持續下去,通常會給股東們帶來不錯的回報。

On a side note, Yifeng Pharmacy Chain's current liabilities are still rather high at 42% of total assets. This effectively means that suppliers (or short-term creditors) are funding a large portion of the business, so just be aware that this can introduce some elements of risk. Ideally we'd like to see this reduce as that would mean fewer obligations bearing risks.

順便提一下,益豐藥房的流動負債仍然相當高,佔總資產的42%。這實際上意味着供應商(或短期債權人)正在資助公司的大部分業務,因此請注意,這可能會引入某些風險。理想情況下,我們希望看到這種情況得到改善,因爲這意味着承擔風險的責任減少了。

What We Can Learn From Yifeng Pharmacy Chain's ROCE

我們可以從益豐藥房的ROCE中學到什麼

In the end, Yifeng Pharmacy Chain has proven its ability to adequately reinvest capital at good rates of return. However, over the last five years, the stock has only delivered a 5.9% return to shareholders who held over that period. So to determine if Yifeng Pharmacy Chain is a multi-bagger going forward, we'd suggest digging deeper into the company's other fundamentals.

最終,益豐藥房已經證明了其在良好的回報率下足夠有效地再投資資本的能力。然而,在過去的五年中,該股票僅爲持有期間的股東提供了5.9%的回報率。因此,爲了確定益豐藥房是否會成爲多倍股票,我們建議深入挖掘該公司的其他基本面。

One more thing to note, we've identified 1 warning sign with Yifeng Pharmacy Chain and understanding it should be part of your investment process.

還有一件事要注意,我們已經確定了與益豐藥房相關的1個警示信號,了解它應該是您投資過程的一部分。

While Yifeng Pharmacy Chain isn't earning the highest return, check out this free list of companies that are earning high returns on equity with solid balance sheets.

儘管益豐藥房的回報率不是最高的,但請查看此免費公司列表,這些公司在擁有 soli balance sheets 的同時獲得了高回報率。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論